VEGFA and colorectal cancer: While the primary focus of the study was on colorectal cancer, it demonstrated the clinical benefits of continuous VEGF inhibition in conjunction with a chemotherapy switch, thereby providing critical evidence for the “cross-line application” of anti-angiogenic therapy.